Natco launches Xtane

New Delhi, Dec 6 (UNI) Hyderabad-based Natco Pharma Ltd today said it has launched Exemestane, a niche product used in the treatment of breast cancer, under the brand name Xtane.

Available as 25 mg tablets, Exemestane is used to treat breast cancer of post-menopausal women who respond to hormonal therapy and are Hormone Receptor positive, a company statement said.

Being the first generic launch of Exemestane, Xtane is priced at around one-sixth of the price of the innovator's brand, in line with the pricing policy of the company, the statement added.

Exemestane would offer a stable and economic option to Hormone Receptor positive patients who are expected to take this medicine for a minimum period of two years.

UNI